Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…
Read More

Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…
Read More
A significant shift in the approach to identifying type 1 diabetes in children is being advocated for, with a new…
Read More
Scientists from Stockholm, Sweden, affiliated with Karolinska Institutet and KTH Royal Institute of Technology, have reported a significant advancement in…
Read More
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Scientists at the forefront of regenerative medicine, based at the esteemed Karolinska Institutet and KTH Royal Institute of Technology in…
Read More
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
The fundamental understanding of how objects move against one another has remained largely unchanged for more than three centuries. Since…
Read More